{
    "code": "52R00091",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52R00091",
    "time": "2019-09-13 03:20:44",
    "許可證字號": "衛部藥輸字第R00091號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "109\/06\/09",
    "發證日期": "104\/06\/09",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA052R0009101",
    "中文品名": "鐳治骨注射液",
    "英文品名": "Xofigo solution for injection",
    "適應症": "本品用於治療去勢抗性攝護腺癌(castration-resistant prostate cancer)病患，其合併有症狀的骨轉移且尚未有臟器轉移者。",
    "劑型": "27D注射液劑",
    "包裝": "6毫升每玻璃小瓶(glass vial) 100支以下盒裝",
    "": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "-->\r\n                    \r\n                        \r\n                            標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "主成分略述": "Radium-223 chloride",
    "主製造廠": {
        "申請商名稱": "1426201100  臺灣拜耳股份有限公司",
        "申請商地址": "台北市信義區信義路五段7號台北101大樓之53至54樓",
        "主製造廠": "",
        "製造廠名稱": "FNO0012100  Institute for Energy Technology"
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "7800000310",
            "成分名稱": "Radium-223 chloride",
            "含量描述": "(syn.: Radium-223 dichloride)",
            "含量": "1100.0000000000",
            "單位": "kBq"
        }
    ],
    "仿單外盒": [
        {
            "title": "R00091 鐳治骨注射液仿單(TW04)-108-07-04.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52R00091&Seq=005&Type=9"
        },
        {
            "title": "衛部藥輸字R00091號 鐳治骨注射液 鉛罐標籤-105-03-22.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52R00091&Seq=007&Type=8"
        }
    ]
}